Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Cellect Biotechnology Ltd. (a foreign private issuer) covers the month of January 2020. The filing discloses a material corporate event: a registered direct offering of American Depositary Shares (ADSs) entered into on January 7, 2020, with an expected closing date of January 10, 2020.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed relates to the capital raise:
- Gross Proceeds: $3.0 million from the issuance of 1,000,000 ADSs.
- Offering Price: $3.00 per ADS (each representing 100 ordinary shares).
- Placement Fee: 6.5% of gross proceeds payable to A.G.P./Alliance Global Partners.
- Debt and Liquidity: The filing text does not provide clear values for existing debt or overall liquidity positions.
Material Changes
The material change reported is the execution of Securities Purchase Agreements for the registered direct offering. This transaction increases the company's share count and capital base. Additionally, the company has agreed to a 45-day lock-up period following the closing, during which it cannot issue or announce the issuance of additional ADSs, ordinary shares, or equivalents, subject to customary exceptions.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook beyond the immediate capital raise. Key risks and contingencies include:
- Closing Contingencies: The offering is subject to customary closing conditions; failure to satisfy these may prevent the transaction from closing.
- Forward-Looking Statements: The company explicitly warns that statements regarding the closing date and future expectations are not guaranteed and may not occur due to factors beyond its control.
- Legal Opinions: The legality of the issuance is subject to the opinion of counsel attached as Exhibit 5.1.
Investor Verification Checklist
- Verify the actual closing of the offering and the receipt of the $3.0 million gross proceeds.
- Confirm the final number of ADSs issued and the post-offering share count.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the company's use of proceeds, as the filing does not specify the allocation of the raised capital.
- Check for any subsequent filings regarding the 45-day lock-up period expiration.